Sydney Lavoie
Pfizer (United States)(US)Centre Hospitalier Universitaire Sainte-Justine(CA)
Publications by Year
Research Areas
Gut microbiota and health, Clostridium difficile and Clostridium perfringens research, Cancer Immunotherapy and Biomarkers, Helicobacter pylori-related gastroenterology studies, Immune Cell Function and Interaction
Most-Cited Works
- → Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut(2016)892 cited
- → Interleukin-10 Receptor Signaling in Innate Immune Cells Regulates Mucosal Immune Tolerance and Anti-Inflammatory Macrophage Function(2014)566 cited
- → CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function(2015)396 cited
- → Metabolite-Sensing Receptor Ffar2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity(2019)318 cited
- → The Crohn’s disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response(2019)147 cited
- → Fusobacterium nucleatum drives a pro-inflammatory intestinal microenvironment through metabolite receptor-dependent modulation of IL-17 expression(2021)136 cited
- → Expression of Free Fatty Acid Receptor 2 by Dendritic Cells Prevents Their Expression of Interleukin 27 and Is Required for Maintenance of Mucosal Barrier and Immune Response Against Colorectal Tumors in Mice(2020)97 cited
- → QseC inhibition as an antivirulence approach for colitis-associated bacteria(2016)57 cited
- → Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. II. Identification and properties of complement receptor type 1 (CR1).(1985)45 cited
- → The Unfolding Story of ATF6, Microbial Dysbiosis, and Colorectal Cancer(2018)14 cited